HOUSTON, TX—(Marketwired – December 06, 2017) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti–cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), announced that its WP1066 drug will receive $2 million in private grant funding for its recently announced Investigational New Drug (“IND”) clearance for a physician–sponsored Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.
“On the heels of our recent IND announcement, we are honored to now announce that a significant private grant has been awarded to help cover the costs of the upcoming brain tumor trial at MD Anderson,” commented Walter Klemp, Chairman and CEO of Moleculin. “We should emphasize that this $2 million grant is in addition to two prestigious SPORE grants awarded by the National Cancer Institute (“NCI”).”
Mr. Klemp added, “The Specialized Programs of Research Excellence (“SPORE”) program was established by NCI to enable the rapid and efficient movement of basic scientific findings into clinical settings and it is now considered a highly prestigious award for promising anticancer technologies. Due to the highly competitive nature of such grants and their and external review processes, we believe they provide further validation of our program and the approach to the treatment of brain cancer and cancer metastasis to the brain. Overall, the combination of all of these funding sources not only allows this trial to begin to move forward, we believe it signals strong support for the development of this class of potential drugs and more specifically, significant enthusiasm for the potential of WP1066 to shut down unwanted cell signaling and to empower the immune system to fight cancer.”
The grants described here do not flow through Moleculin's financial statements, but instead are applied to the cost of preclinical and clinical activities at and conducted by MD Anderson.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of anti–cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule portfolios in development, one of which is focused on the modulation of hard–to–target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com.
Some of the statements in this release are forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward–looking statements in this press release include, without limitation, the ability of the WP1066 to demonstrate safety and efficacy in brain tumor patients. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward–looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward–looking statements. Moleculin Biotech has attempted to identify forward–looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward–looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10–K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10–Q filings and in our other public filings with the SEC. Any forward–looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward–looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.